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Background: Bone-targeted agents are usually administered to breast cancer patients with bone
metastases every 3–4 weeks. Less frequent (‘de-escalated’) treatment may provide similar beneﬁts with
improved safety and reduced cost.
Methods: To systematically review randomised trials comparing de-escalated treatment with bone-
targeted agents (i.e. every 12–16 weeks) to standard treatment (i.e. every 3–4 weeks), a formal systematic
review of the literature was performed. Two individuals independently screened citations and full text
articles. Random effects meta-analyses of clinically important outcomes were planned provided
homogeneous studies were identiﬁed.
Results: Five relevant studies (n¼1287 patients) were identiﬁed. Sample size ranged from 38 to 425.
Information on outcomes including occurrence of SREs, bone pain, urinary N-telopeptide concentrations,
serum C-telopeptide concentrations, pain medication use and safety outcomes was not consistently
available. Two trials were non-inferiority studies, two dose-response evaluations and one was a pilot
study. Bone-targeted agents use varied between studies, as did duration of prior therapy. Patient
populations were considered heterogeneous in several ways, and thus no meta-analyses were
performed. Observations from the included studies suggest there is potential that 3 month de-
escalated treatment may provide similar beneﬁts compared to 3–4 weekly treatment and that lower
doses of zoledronic acid and denosumab might be equally effective.
Conclusions: Studies comparing standard and de-escalated treatment with bone-targeted agents in
breast cancer are rare. The beneﬁts of standard treatment compared to de-escalated therapy on
important clinical outcomes remain unclear. Future pragmatic studies must be conducted to determine
the merits of this approach.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Bone is the most common site of breast cancer recurrence [1].
Patients diagnosed with bone metastases are presently treated
with bone-targeting agents, such as bisphosphonates and RANK
ligand antibodies, every 3–4 weeks for the remainder of their life
[2]. Historically, the frequency of dose administration was devel-
oped partly on schedules based on hypercalcaemia trials and. This is an open access article und
miology, Center for Practice
stitute, Box 201, 501 Smyth
37 8899x73827.
dison@ohri.ca (C.L. Addison),
n@ohri.ca (D. Fergusson),
.on.ca (M. Clemons).limited bone marker studies but also for convenience rather than
efﬁcacy and safety purposes, as it allowed investigators to deliver
bone-targeted agents at the same time patients were also receiv-
ing chemotherapy (i.e. every 3 weeks) or every 4 weeks if the
patient was receiving endocrine therapies. However, this rationale
ignores the pharmacokinetics of BTAs, which may have a half-life
in bone of many years [3,4], and the modest absolute magnitude of
beneﬁt of these agents [5].
Despite the widespread use of BTAs, the question around
optimal dose and dosing intervals remains unanswered [6–8]. This
is particularly important given that drug induced toxicities are
directly related to both the potency of the agent and also the
cumulative dose received. Indeed, the incidence of BTA-associated
osteonecrosis of the jaw is now approaching 10% in some selected
chart reviews and online registries, making this by far the moster the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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reported pilot studies [10–13] have suggested that patients can
derive similar palliative beneﬁts from bone-targeted agents when
given at less frequent intervals, while others are ongoing [14].
While we have previously used the term de-escalation to imply
reduced frequency of administration [11] it can also relate to a
reduced dose per unit time. In order to assess the need for further
randomized controlled trials of standard 3–4 week treatment with
bone-targeted agents in breast cancer patients with metastatic
disease compared to de-escalated treatment, we performed a
systematic review of the published literature.2. Methods
2.1. Study question and inclusion criteria
Our systematic review was designed to summarize available
information addressing the following research question: “Does de-
escalated treatment (i.e. every 3–4 months) with bone-targeted
agents in breast cancer patients with metastatic disease provide
similar beneﬁt to 3–4 weekly treatment?” The Population–Inter-
vention–Comparator–Outcome–Study Design (PICOS) framework
was employed to structure the research question and to design the
literature search. The population of interest was breast cancer
patients with metastatic disease to bone; the intervention of
interest was de-escalated/de-intensiﬁed treatment with any
bone-targeted agent (denosumab, pamidronate, zoledronate, iban-
dronate, clodronate), while the comparator was standard 3–4
weekly treatment with any bone-targeted agent. Outcomes of
interest included skeletal related events, bone pain, and quality
of life, and only randomized controlled trials were considered
eligible.
Inclusion criteria used during Stage 1 (i.e. citation review) and
Stage 2 (i.e. full text review) screening closely mirrored the above
PICOS criteria, with addition details used to determine inclusion
status consisting of the following details: (1) studies were required
to include patients with radiological or pathological diagnosed
bone metastases from breast cancer; (2) any dose of bone-targeted
agent being used was considered to be eligible; (3) no speciﬁc
criteria relating to duration of treatment with a bone-targeted
agent prior to study entry was employed. The clinical outcomes of
interest, skeletal related events (SREs), were deﬁned to consist of
multiple events which included pathologic fractures, radiotherapy/
surgery to bone, spinal cord compression and hypercalcaemia of
malignancy. Only validated measures of bone pain [e.g. The Brief
Pain Inventory (BPI) and Functional Assessment of Cancer Therapy-
Bone Pain (FACT-BP)] and quality of life (e.g. FACT-G, EORTC QLQ-
BM22, EORTC QLQ-C15-PAL) were accepted. While the above noted
outcomes were of primary interest, studies of relevant design,
treatment and patients were still retained even if limited to other
outcome measures in order to present a complete overview of the
literature.
2.2. Literature search
An information specialist (KC) designed and executed an
electronic literature search to seek relevant citations for this
systematic review from Ovid Medline (1946-present), PubMed
(for non-Medline records), the Cochrane Library (search run March
13, 2013), and from the three major annual oncology conferences
held worldwide since 2010 (American Society of Clinical Oncology,
the European Society for Medical Oncology, and the San Antonio
Breast Cancer Symposium). The full literature search is provided as
a supplement to this review (Appendices 1–3). As one of the
applicants is also an expert in this ﬁeld (MC), awareness of thearea and contact with other experts was also used as an additional
means to identify relevant ongoing work. These efforts did not
identify any additional publications.2.3. Study screening, selection, and risk of bias assessment
Two reviewers with expertise in oncology (MC, CA) reviewed
the citations that were retrieved from the literature search
independently. Stage 1 review consisted of screening of titles
and abstracts only, while Stage 2 screening consisted of screening
of full text articles where available to conﬁrm study selection, or in
the case of meeting abstracts, these were limited to their existing
text. Following screening at each stage, the reviewers planned to
meet to resolve any discrepancies and to consult a third party (BH)
if needed. Results from the screening process are presented in a
PRISMA ﬂow diagram (Fig. 1) [15]. A list of included and excluded
studies is provided in Appendix 4.
Risk of bias of all eligible randomized controlled trials was to be
assessed using the Jadad scale [16]. However, it was found that
only one included study was published in manuscript form, while
the remaining studies were published in abstract form only. As a
consequence, an assessment of only one eligible study [10] could
be performed. Data collection from relevant studies was per-
formed by the two reviewers using a pre-designed extraction
form.2.4. Data analysis
If deemed appropriate following exploration of study and
patient characteristics to ensure sufﬁcient clinical and methodo-
logical homogeneity across studies, we planned to pursue meta-
analyses using random effects models to combine data for out-
comes of interest across relevant studies, as described in the
Cochrane Handbook [17]. Summary estimates were planned to
be reported using appropriate point estimates and corresponding
95% conﬁdence intervals, along with forest plots of all study
estimates to provide visualization of variability in ﬁndings from
study to study for each outcome. Statistical heterogeneity was also
to be assessed using both the Cochrane Q statistic and the I2
statistic. Following review of the included studies' characteristics,
in particular with regard to patient populations, it was judged by
the authors there were important clinical differences that pre-
cluded the data from meta-analysis. These differences are dis-
cussed in the summary of ﬁndings below. Given these differences,
a narrative approach to summary of study-speciﬁc results was
employed.3. Results
3.1. Eligible studies
Our electronic literature search identiﬁed a total of 777 unique
citations for review following removal of duplicates. Stage
1 screening identiﬁed a total of 7 citations which were considered
potentially eligible for inclusion; 4 were meeting abstracts with
no further information available which were thus included
as is at Stage 2 screening, while 3 were associated with full
manuscripts that were retrieved and screened. After Stage
2 screening, a total of 5 studies consisting of 1287 patients were
included [10,11,13,18,19] while 2 were excluded because, while on
topic, they were non-randomised, single-arm studies and thus did
not fully meet pre-speciﬁed inclusion criteria [20,21]. Fig. 1 pro-
vides an overview of the process of study selection.
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Fig. 1. Systematic review supplement: PRISMA ﬂow diagram.
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Two of the ﬁve studies selected for inclusion were described in
abstract form only, and thus available information regarding these
studies was limited. Characteristics of the studies in terms of
funding source, patient inclusion criteria, study design and out-
comes assessed are described in Table 1. Brieﬂy, 80.0% (4/5) of the
studies completed enrollment [10,11,18,19], while the remaining
study closed early due to poor patient accrual [13]; three of the
abstracts/publications describing these studies were published in
2012, while the remaining two were published in 2011 [19] and
2007 [18]. The number of enrolled patients ranged from a mini-
mum of 38 [11] to a maximum of 425 [10], and 80% (4/5)
[10,13,18,19] were funded by industry. Study duration was 10
months in one study [19], 1 year in three studies [10,11] and
2 years in one study. [13] All trials enrolled patients with meta-
static breast cancer, one [11] used additional study entry criteria
based on low baseline serum C-telopeptide concentrations
(o600 ng/L), and one also enrolled patients with multiple mye-
loma [19]. Three studies were open label, and involved the
comparison of a standard treatment frequency (i.e. q3–4 weeks)
compared to a de-escalated therapy (i.e. q12–16 weeks) [11,13,10].
One study was a double-blinded comparison of 0.4 mg/2 mg/4 mg
zoledronic acid q4 weeks for up to 10 months and 90 mg
pamidronate q4 weeks [19], while another compared 5 groups
receiving different denosumab regimens against open label IV-
bisphosphonate therapy as chosen as physicians' discretion [18].
The bone targeted agents used within studies were either pami-
dronate [11,18,19], zoledronate [10,13,18,19], denosumab [18] or
ibandronate [18]. The minimum extent of bisphosphonate use
prior to enrollment varied from 0 months [13] to ≥3 months [11],
to 9–12 months [10].The incidence of skeletal morbidity was measured in all
5 studies (in terms of either skeletal event rate or the skeletal
morbidity rate), bone pain was assessed using varied outcome
measures in 2 studies [11,19], use of pain medication in 1 study
[11], serum C-telopeptide concentrations in 1 study [11], urine N-
telopeptide in 2 studies [13,18] and quality of life in 1 study [11].
Unfortunately, numeric details of ﬁndings for these outcomes
were not always reported.
There were important differences between the trials in terms of
prior bisphosphonate therapy of the enrolled populations. Three
studies enrolled patients with none at all [13,18,19], one required a
minimum of 3 months [11] treatment with no upper limit of use,
and one required speciﬁcally 9–12 months [10]. The requirement
for 9–12 months of 4-weekly bisphosphonate is suited to a more
ﬁt population without kidney damage during that time frame,
which is an important difference in study populations. The
REFORM study [11] included patients with a longer history of
metastatic disease than the other studies. Given that metastatic
breast cancer would additionally be characterized by limited
survival and reduced performance status with time, it is likely
that these patients would have a worse performance status than
the patients in other studies where randomization was performed
earlier in the patients' disease journey. This information was not
available from the study manuscripts. The REFORM [11] study
incorporated eligibility screening of patients for the study by
markers of bone turnover, while the BISMARK [13] and ZOOM
studies did not, thus meaning that the REFORM cohort are likely
quite distinct from the other two, as they are effectively screening
out patients at higher risk of skeletal morbidity. The Berenson
study [19] was a dose-response study involving approximate 2/3
breast cancer and 1/3 multiple myeloma patients with no separa-
tion of outcomes for the two tumor types. As noted earlier, as a
Table 1
Summary of relevant study characteristics.
Author (year) Industry
funded?
Study Design Information
(duration, blinding/AC, etc)
Sample size Patient inclusion
criteria
Relevant patient
demographics
Outcomes assessed Study
duration
Study status
(complete/when,
ongoing/when
expected to
complete)
Amir et al. [10] No Open label, randomised, Q4
weekly vs q12 weekly
pamidronate
38 MBC (bone mets)
Baseline serum CTx
o600 ng/L
≥3 months of
prior BP use
CTx, Pain (FACT-BP,
BPI),SREs, pain
medication, BAP
1 yr Complete—peer-
reviewed
publication
Amadori et al.
[9]
Yes Open label, randomised Q4
weekly vs q12 weekly
zoledronic acid
425 MBC (bone mets) 9–12 months of
prior zoledronic
acid
SMR; number of
SREs/pt/yr, time to
ﬁrst SRE, bone pain,
bone marker (N-
telopeptide of type I
collagen; NTX)
levels, and safety
1 yr Complete—
abstract
presentation
Coleman et al.
[12]
Yesa Open label, randomised
S-ZOL 3–4 w or M-ZOL (15–
16 w; 8–9 w or 3–4 w) if
urine NTX levels were
o50, 50–100, 4100 nmol/
mmol creatinine
289 MBC (bone mets) No prior BP SREs 2 yr Completed 2 year
follow-up despite
early closure
Berenson et al.
[19]
Yes Double-blind, randomised
zoledronic acid 0.4, 2 or
4 mg (4 w for up to 10
months) versus
pamidronate 90 mg (4 w
for up to 10 months)
280 MBC or multiple
myeloma; radiologic
evidence of 1 or
more osteolytic
lesions; patients
with myeloma
required history of
1 or more prior SREs
or chemotherapy
failure
No prior BP Need for radiation;
SREs; bone mineral
density;
performance status;
pain score; analgesic
score; safety
10 months Complete—peer-
reviewed
publication
Lipton et al. [18] Yes Randomised, blinded study
of ﬁve denosumab
regimens (4 w 30 mg,
120 mg or 180 mg; or 12 w
60 mg or 180 mg) and an IV
BP regimen (4 w use of
physician’s choice amongst
zoledronic acid,
pamidronate or
inbandronate)
255 MBC No prior IV BP Bone turnover
marker urine
N-telopeptide
corrected for urine
creatinine; SREs;
safety
13 weeks
for
biomar-
kers
Complete—peer-
reviewed
publication
BAP¼bone alkaline phosphatase, CTx¼serum C-telopeptide; MBC¼Metastatic breast cancer; BP¼bisphosphonate, NTX¼ urine N-telopeptide, yr¼year.
a Part funded by Novartis.
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it was decided by the authors that the ﬁve included studies were
not sufﬁciently homogeneous for meta-analysis. A summary of
study-speciﬁc ﬁndings was thus prepared. Provided next is a
narrative review of the design features and reported ﬁndings for
each of the included studies.
3.3. The ZOOM study [10]
The ZOOM trial [10] was a phase III prospective, randomized,
open-label, multicenter study designed to assess non-inferiority of a
standard 3–4 weekly bisphosphonate and de-intensiﬁed bispho-
sphonate treatment. The primary endpoint was the skeletal morbid-
ity rate (SMR; deﬁned as the mean number of SREs per patient per
year) based on a sample of 425 patients. Patients had to have
received between 9–12 months of standard 3–4 weekly zoledronic
acid prior to randomization. The results showed that the SMR was
similar between treatment arms: 0.26 (95% conﬁdence interval [CI]¼
0.15–0.37) in the de-intensiﬁed arm vs. 0.22 (95% CI¼0.14–0.29) in
the q4 weekly arm. The mean difference and corresponding 95% CI
were 0.04 (−0.09 to 0.17). The upper limit of the conﬁdence interval
(0.17) was less than the re-calculated non-inferiority margin of 0.19,
indicating that the efﬁcacy of the q12 week arm was not inferior to
the q4 week arm. Safety analyses showed that zoledronic acid was
well tolerated. Renal adverse events were reported in similar
proportions of patients in both arms, and 7 cases of osteonecrosisof the jaw were reported (1.65% overall; 4 cases in the 3–4 weekly
group vs. 3 in the de-intensiﬁed group). The authors stated that SMR
was similar between the study arms in order to conﬁrm non-
inferiority of bone-targeted therapy every 12 weeks, however
acknowledged that a larger deﬁnitive Phase III trial is required.
3.4. The BISMARK study [13]
The hypothesis of treating patients based on markers of bone
resorption was tested in a large National Cancer Research
Institute-supported Phase 3 clinical trial in the United Kingdom
(BISMARK, EudraCT no. 2005-001376-12). The BISMARK study [13]
looked at use of a biomarker of bone turnover to determine
whether patients could receive zoledronic acid q4 or as needed
on a schedule based on the N-telopeptide (NTX) concentrations at
each clinic visit. Under the marker-directed schedule, patients
received zoledronic acid 4 mg intravenously every 3–4 weeks (if
NTX level was 4100 nM/mM creatinine), every 8–9 weeks (if NTX
level was 50–100 nM/mM creatinine), or every 15–16 weeks (if
NTX level was o50 nM/mM creatinine). The primary endpoint
was development of an on-study SRE, while secondary endpoints
included quality of life (QLQ-C30 and the QLQ-BR23 breast-speciﬁc
module), pain, analgesic use, health economics, change in systemic
therapy, and survival from the time of randomization. Despite a
planned sample size of 1400 patients, the trial was closed after
289 patients due to poor accrual, and is no longer active. Data on
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being underpowered to demonstrate non-inferiority, the results
suggested that adjustment of dosing schedule based on NTX may
be a sub-optimal strategy, as patients who received the biomarker
driven arm did numerically have more SREs. Ultimately, BISMARK
was unable to answer the primary study outcome as to whether or
not biomarkers of bone turnover could be used to drive treatment
with zoledronic acid or not [13].
3.5. The REFORM study [11]
Amir et al. [11] recently published the results of the REFORM study,
which was designed to see if an RCT of de-intensiﬁcation of bone-
targeted therapies was feasible. It was a pilot randomised, non-
inferiority study in which patients with breast cancer and bone
metastases with low-risk disease as determined by serum
C-telopeptide (CTx) levels o600 ng/L after ≥3 months of pamidronate
treatment were enrolled. Patients were randomly allocated 1:1 into
the experimental (q12 weekly pamidronate) and control (q3–4 weekly
pamidronate) groups. CTx levels were checked every 12 weeks across
a 48-week time period. Those remaining in the low-risk group
continued to receive their allocated treatment, while those whose
CTx levels rose above 600 ng/L were switched back to treatment every
4 weeks. Number of SREs and pain scores (BPI and FACT-BP ques-
tionnaires) were recorded for each enrolled patient. The results
showed that of 38 randomised patients, 14 control group participants
(73.7%) and 13 de-escalated group participants (68.4%) maintained
CTx in the low risk range for the duration of the study (test of
2 proportions, p¼0.64). There were no statistically signiﬁcant differ-
ences in pain scores between the groups. Interestingly, despite a time-
dependent increase in CTx in the de-escalated group, this was not
associated with an increase in SREs over the one year study period.
The results of this study showed that it is feasible to perform
randomised trials of de-escalated therapy. Of the 54 patients
approached about the study, 44 agreed to be consented, conﬁrming
signiﬁcant patient interest in de-escalation of bone-targeted therapies.
3.6. Berenson et al. [19]
Berenson et al. [19] reported ﬁndings from a randomized,
double-blinded, multi-center study of 280 patients which evalu-
ated the dose-response relationship for zoledronic acid (0.4 mg,
2 mg or 4 mg) when administered as a 5-minute infusion in
patients with malignant osteolytic lesions as a result of breast
cancer or multiple myeloma. A group of patients was also
randomized to pamidronate 90 ms. Patients were not eligible if
they had previously been treated with bisphosphonates. The study
collected data regarding the need for radiation therapy (the
primary outcome), other SREs, observed changes in bone mineral
density, performance status, bone markers, and measures of pain
and analgesia use. Study ﬁndings showed that the pamidronate
group (18% vs 24%) and the two highest dose groups of those
receiving zoledronic acid (2.0 mg: 19% vs 24%; 4.0 mg: 21% vs 24%)
were all found to be associated with a statistically signiﬁcantly
lower frequency of the need for radiation therapy compared to the
0.4 mg zoledronic acid group. Proportions of patients in the
0.4 mg, 2 mg, 4 mg zoledronic acid groups and pamidronate group
that had 1 or more SREs were 46%, 35%, 33%, and 30%, respectively;
amongst the ﬁrst 25% of patients in each group who experienced
an SRE, no difference in the median time to ﬁrst SRE was found
between zoledronic acid groups, while the difference between the
0.4 mg group and the pamidronate group reached statistical
signiﬁcance (167 days versus 254 days). Differences in pain scores
between treatment groups were not clinically important, though
more patients receiving 4 mg zoledronic acid (67%) reported a pain
decrease during the study than in the pamidronate group (51%)and those receiving 0.4 mg (51%) and 2 mg zoledronic acid (48%).
Unfortunately, the interval between imaging tests was not stated
in the paper, and the combined data for breast cancer and multiple
myeloma data is presented. Essentially however, there was no
signiﬁcant difference between 2 mg and 4 mg zoledronic acid in
terms of SREs and the authors concluded that a 5 min infusion of
2–4 mg zoledronic acid was, at minimum, as effective as 90 mg
pamidronate administered over two hours.
3.7. Lipton et al. [18]
Lipton et al. [18] reported ﬁndings from a randomized, multi-
center, partially blinded study which randomized 255 women
with metastatic breast cancer to receive either one of ﬁve
denosumab regimens (30 mg, 120 mg or 180 mg every 4 weeks;
60 mg or 180 mg every 12 weeks) or open label IV-bisphosphonate
therapy every 4 weeks as chosen by the consulting physician
(using either zoledronic acid, pamidronate or ibandronate). The
study’s primary outcome of interest was 13-week change in bone
turnover marker urine N-telopeptide corrected for urine creati-
nine, while secondary outcomes included related bone turnover
marker measures, the occurrence of SREs, and safety. Eligible
patients could not have received prior IV bisphosphonate treat-
ment, and were followed for 56 weeks. The biomarker studies
showed no differences between the doses or dosing intervals of
denosumab or between the denosumab and the bisphosphonate
arms. Median time to ﬁrst on-study SRE was found to be compar-
able across the denosumab and IV bisphosphonate managed
groups based on Kaplan-Meier analysis, while totals of 9% of
subjects across the denosumab groups and 16% in the IV bispho-
sphonates group experienced at least one SRE. The authors
concluded that denosumab may produce results similar to IV
bisphosphonates in terms of both suppression of bone turnover
and the risk of skeletal related events.4. Discussion and conclusions
4.1. Summary of ﬁndings
In this systematic review, we performed a systematic search of
the literature and recent conference abstracts frommajor oncology
conferences to identify randomized controlled trial evidence
evaluating the merits of de-escalated treatment (e.g. every 12
weeks) of breast cancer patients with bone-targeted agents in
comparison to current standard practice of every 3–4 weeks. Our
search identiﬁed a total of only ﬁve relevant studies that enrolled a
total of just 1287 patients, and one of these studies was closed
early as a consequence of slow patient accrual. The ﬁve studies had
varied inclusion criteria and study endpoints. Sample size across
studies ranged from 38 to 425, four of ﬁve were industry funded,
and three were reported in 2012 (two in abstract form only) while
the others were reported in 2001 and 2007. Four studies were of
approximately one year in duration while the ﬁfth was planned for
two years of follow-up, however it terminated early due to poor
patient enrollment. While studies indicated collection of several
outcomes including the occurrence of SREs, bone pain, N-telopep-
tide, serum C-telopeptide, pain medication use and safety out-
comes, information on these outcomes was not consistently
available, in particular due to limited detail in those studies
described as abstracts.
Two trials (the ZOOM [10] and BISMARK [13] studies) were
planned as non-inferiority studies, while the REFORM [11] study
was designed as a pilot study to assess feasibility. Other differences
between the studies included the bisphosphonates used (i.e. zole-
dronic acid, pamidronate, denosumab and ibandronate) and the
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(BISMARK [13], Lipton et al. [18], Berenson et al. [19]), any duration
≥3 months (REFORM [11]), and 9–12 months (ZOOM [10]). The trials
are therefore quite heterogeneous in design and patient population.
The similarities and differences between these studies conﬁrm that
there is indeed considerable interest in de-escalated bone-targeted
therapy, however there is clearly a need for larger deﬁnitive studies
to be performed if there is to be a change in practice.
4.2. Implications of existing studies for future research
The ZOOM study is the only study presented to date that
used SRE rates to compare standard and de-escalated treat-
ment groups. In recent years, many researchers have used
biomarkers of bone resorption as a surrogate of SRE risk to
design smaller trials assessing optimal doses [22], frequency of
administration [11], and choice of bone-targeted agent [23,24].
The role of bone turnover markers for predicting SRE risk in
longer term studies is increasingly being questioned [13], and
they are best only to be used as a surrogate for planning larger
deﬁnitive studies [25].
As a consequence of the low study accrual observed within the
BISMARK trial [13], practice changing results were not generated.
Personal communications with the primary investigator of the
study suggested that the study was, in retrospect, too complex in
its design, and participating physicians found it overly complicated
to wait for the NTx result (the sample was supplied when the
patient came to clinic, however the result came days later) before
booking the next scheduled zoledronic treatment as opposed to
simply booking it in the clinic when seeing the patient (PI: R.
Coleman, personal communication). Perhaps the most important
lesson to be learned from the BISMARK study is that clinical trial
design in this setting and patient population must be pragmatic.
In the REFORM trial [11], despite a time-dependent increase in
CTx in the de-escalated group, there was no increase in SREs over the
one year study period. The results of this study showed that it is
feasible to perform randomised trials of de-escalated therapy; of the
54 patients approached about the study, 44 agreed to be consented,
conﬁrming signiﬁcant patient interest in de-escalation of bone-
targeted therapies. This is important, as it conﬁrms the results of
ZOOM [10] (i.e. an equal number of SREs in both the standard and the
de-intensiﬁed arms), but also shows the need for a study longer than
one year duration to see if the rise in biomarkers is associated with
more SREs over the long term, or are not associated with risk of SRE
in long-term bisphosphonate treated patients.
The Berenson study [19] is of historical interest as the 2 mg
and 4 mg zoledronic acid appeared to show no signiﬁcant
differences in their effects on SREs, and yet it was the higher
dose that went on to become the global standard dose. While
the Lipton study [18] enrolled 6 blinded cohorts of denosumab
with differing doses and dosing-intervals compared with an
open label bisphosphonate arm, no difference in biomarkers
was seen and it was suggested that denosumab may result in
less SREs than the standard bisphosphonate arm. However, the
unblended nature of the bisphosphonate therapy makes this
difﬁcult to control for.
4.3. Other relevant work of note
Two studies were not included in our systematic review
because they were non-randomized, single arm studies; how-
ever they also warrant mention. Following the REFORM study,
the same research group performed a larger single arm study
called the TRIUMPH study, designed to assess the feasibility of
using bone turnover markers to identify low-risk patients on ≥3
months of q4 weekly pamidronate and decreasing theirtreatment frequency to every 12 weeks [21]. As in REFORM, if
there was a rise in serum CTx, patients were removed from the
study and switched back to q4 weekly treatment. The primary
goal was to assess the ability to suppress bone turnover markers
in low-risk patients with a 12-week regimen over the one year
study period. While analysis is still ongoing, the results thus far
have shown that of the 71 patients on study, only 3 have come
off due to the occurrence of SREs; this is a lower percentage
than observed in the REFORM study. Twelve patients have come
off for elevation of CTx, however as in the REFORM study, the
SREs were not correlated with rising CTx. Thus, this study to
date has three important ﬁndings: (1) patients and physicians
are highly motivated to enter de-escalation studies, (2) SRE data
needs to be extended beyond one year given the long survival of
these patients, and (3) markers of bone-turnover are not useful
as the primary endpoint of a large trial as they are not acting as a
surrogate for SRE risk.
In the single-arm SubDue study, Simmons et al. [20] explored
whether the upfront administration (i.e. bone-targeted agent
naïve patients) of zoledronic acid every 3–4 weeks is the
optimal dosing frequency or due to convention [20]. The
purpose of the study was to determine the duration of suppres-
sion of bone turnover by zoledronic acid in a population of
bisphosphonate naive metastatic breast cancer patients. The
study enrolled 26 patients and a single dose of zoledronic acid
was given at week 0, with biomarkers of bone turnover (serum
CTx) being measured bi-weekly. Pain scores and quality of life
data were collected every 4 weeks. Patients remained on study
if CTx remained suppressed, but came off study as soon as
escape from suppression was noted (deﬁned as a rise450% of
baseline value). At 12 weeks, 73% (95% CI 56%-90%) of patients
had continued suppression of bone turnover demonstrated by
serum CTx. The patients that escaped CTx suppression did so at
a median of 8 weeks after ﬁrst infusion of zoledronic acid (range
8–10 weeks). Quality of life scores and pain medication use did
not change appreciably during this period. Again, this biomarker
driven study suggests that bone-targeted agents may not need
to be given at conventional intervals in the majority of patients,
and may safely be withheld without increased risk to morbidity
or decline in quality of life over a 12 week period. While
TRIUMPH and SubDue are of interest, they did not fulﬁll the
criteria for this systematic review as they were neither rando-
mised or used SREs as their primary endpoints.4.4. Study limitations
There are limitations to be noted regarding our systematic
review. First, while our search did not include EMBASE, we did
perform a rigorous search of multiple databases (Medline, PubMed
and the Cochrane Library), and we are not aware of any further
work being presented. The topic is also relatively new, and the
strength of our literature search was seeking additional informa-
tion from the past three years from key oncology conferences to
seek the availability of timely information. Three of the works
were found to be published within the past year. A second
limitation is the lack of speciﬁc detailed information that was
available from some of the included studies given that two were
published in abstract form only, which thus precluded the ability
to assess the risk of bias in these trials. Third, the extent of
available data from the included trials with regard to more
clinically important outcomes such as skeletal related events was
limited and study duration was often only one year, which may not
be adequate for the observation of important differences between
treatment regimens. Both design deﬁciencies contribute to the
need for further research to address the current knowledge gap
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therapy with bone-targeted agents.5. Conclusions
We identiﬁed a clear knowledge gap with regard to establish-
ing the clinical beneﬁts of de-escalated bone targeted agent
therapy in breast cancer patients in comparison to current
standard practice. Currently available research has been shown
to have several deﬁciencies with regard to comparing these
approaches, and a knowledge gap currently remains as to their
relative impact on patient outcomes. If future studies can demon-
strate comparable beneﬁts and safety of less frequent and/or lower
dose treatment, the quality of life beneﬁts to patients and the
economic beneﬁts to the health care system represent important
changes in the ﬁeld. Pragmatic studies encompassing lessons
learned in terms of study design from past research and involving
patient-centered outcomes are needed to explore these issues and
address current questions regarding the relative effectiveness and
safety of these approaches to treating patients with breast cancer
and metastatic bone disease.Author contributions
MC and CA were responsible for proposal of the clinical
research question. BH, CA, KC and MC contributed to authorship
of the initial draft of the manuscript. All authors contributed to
identiﬁcation of methods for the systematic review and to critical
revision and approval of the ﬁnal version of the manuscript.
Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
Appendix 1. Systematic review supplement: SUMMARY of
electronic literature search
Ovid MEDLINE(R) In-process and other non-indexed citations
and ovid MEDLINE(R) 1946 to present; ovid MEDLINE(R) daily
update February 08, 2013.# Searches Results1 Breast Neoplasms/ 197,472
2 Carcinoma, Ductal, Breast/ 10,468
3 Inﬂammatory Breast Neoplasms/ 113
4 ((breast or mamma or mammary) adj3 (cancer*
or carcinoma* or neoplasm* or tumor* or
tumor*)).ti,ab.206,3415 or/1–4 256,053
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